Eli Lilly announces Lilly TuneLab
In return for access, selected biotech partners contribute training data, which fuels continuous improvement for the benefit of others in the ecosystem and ultimately patients.
Here’s a recent announcement that might be valuable for life science and biotechnology start-ups.
Eli Lilly and Company recently announced the launch of Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data. Lilly estimates that this first release of AI models includes proprietary data obtained at a cost of more than $1 billion, representing one of the industry’s most valuable datasets used to train an AI system available to biotechnology companies.
“Lilly has spent decades building comprehensive datasets for drug discovery. Today, we’re sharing the intelligence gained from that investment to help lift the tide of biotechnology research,” said Daniel Skovronsky, M.D., Ph.D., Chief Scientific Officer and President of Lilly Research Laboratories and Lilly Immunology. “Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists. By opening up access, we hope to accelerate the creation of new medicines for patients who need them.”
In return for access, selected biotech partners contribute training data, which fuels continuous improvement for the benefit of others in the ecosystem and ultimately patients.
Lilly TuneLab is the newest addition to Lilly Catalyze360’s set of offerings for Lilly’s biotech partners, which includes strategic capital through Lilly Ventures, state-of-the-art laboratory facilities at Lilly Gateway Labs, and drug development expertise via Lilly ExploR&D.
According to BioPharma Dive, about a dozen start-ups have joined up so far.
Like what you've read?
Forward to a friend!